Dermira reports Phase III hyperhidrosis data

Dermira Inc. (NASDAQ:DERM) said DRM04 met both co-primary endpoints in the Phase III ATMOS-2 trial and one of two co-primary

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE